

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Last Update: Dec 24, 2024

A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

ClinicalTrials.gov Identifier:

[NCT05624749](#)

Novartis Reference Number: CVAY736F12302

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The trial will evaluate efficacy, safety and tolerability of Ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE). A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of Ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)

Condition

Systemic Lupus Erythematosus

Phase

Phase3

Overall Status

Recruiting

Number of Participants

280

Start Date

Apr 21, 2023

Completion Date

Jan 23, 2029

Gender

All

Age(s)

12 Years - 100 Years (Child, Adult, Older Adult)

Interventions

Drug

ianalumab

ianalumab s.c. monthly

Drug

placebo

placebo s.c. monthly

Eligibility Criteria

Inclusion Criteria:

- * Male and female participants aged 12 years or older at the time of screening, or limited to 18 years or older in European Economic Area countries and other countries where inclusion of participants below 18 years is not allowed.
- * Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior to screening.
- * Elevated serum titers at screening of anti-nuclear antibodies $\geq 1:80$ as determined by a central laboratory with a SLE-typical fluorescence pattern.
- * Currently receiving CS and/or anti-malarial treatment and/or another disease-modifying antirheumatic drug (DMARD) as specified in the protocol.
- * SLEDAI-2K criteria at screening: SLEDAI-2K score ≥ 6 points, excluding points attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome"
- * BILAG-2004 disease activity level at screening of at least 1 of the following:
 - * BILAG-2004 level 'A' disease in ≥ 1 organ system, Or
 - * BILAG-2004 level 'B' disease in ≥ 2 organ systems
- * Weigh at least 35 kg at screening

Exclusion Criteria:

- * Prior treatment with ianalumab
- * History of receiving following treatment I) high dose CS, calcineurin inhibitors, JAK or other kinase inhibitors or other DMARD (except as listed in inclusion criteria) administered within 12 weeks prior to screening II) cyclophosphamide or biologics such as immunoglobulins (intravenous or s.c.), plasmapheresis, anti-type I interferon receptor biologic agents, anti-CD40 agents, CTLA4-Fc Ig or B-cell activating factor (BAFF)-targeting agents administered within 24 weeks prior to screening; belimumab administered within 12 weeks prior to screening. III) any B cell-depleting therapies, other than ianalumab administered within 36 weeks prior to randomization or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower). IV) Traditional Chinese medicines administered within 30 days prior to randomization
- * Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection
- * Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- * Evidence of active tuberculosis infection
- * History of primary or secondary immunodeficiency, including a positive human immunodeficiency virus (HIV)

test result at screening

* Any one of the following abnormal laboratory values prior to randomization:

* Platelets $< 25000 / \text{mm}^3$ ($< 25 \times 10^3 / \mu\text{L}$)

* Hemoglobin (Hgb) $< 8.0 \text{ g/dL}$ ($< 5 \text{ mmol/L}$), or $< 7.0 \text{ g/dL}$ ($< 4.3 \text{ mmol/L}$) if related to participant's SLE such as in active hemolytic anaemia

* Absolute neutrophil count (ANC) ($< 0.8 \times 10^3 / \mu\text{L}$)

* Severe organ dysfunction or life-threatening disease at screening

* Presence of severe lupus kidney disease as defined by proteinuria above 2 g/day or equivalent using spot urine protein creatinine ratio, or serum creatinine greater than 2.0 mg/dL (176.84 $\mu\text{mol/L}$), or requiring immune-suppressive induction or maintenance treatment at screening

* Receipt of live/attenuated vaccine within a 4-week period before first dosing

* Any uncontrolled, co-existing serious disease, which in the opinion of the investigator will place the participant at risk for participation or interfere with evaluation for SLE-related symptoms

* Non-lupus conditions such as asthma, gout or urticaria, requiring intermittent or chronic treatment with systemic CS

* History of malignancy of any organ system other than localized basal cell carcinoma of the skin or in situ cervical cancer

* Pregnant or nursing (lactating) women.

* Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while on study treatment and for 6 months after stopping of investigational drug.

* Any surgical, medical, psychiatric or additional physical condition that may jeopardize participation in this study

Argentina

Novartis Investigative Site

Recruiting

Ciudad Autonoma de Bs As,Buenos Aires,C1015abo,Argentina

Novartis Investigative Site

Recruiting

La Plata,Buenos Aires,B1900awt,Argentina

Novartis Investigative Site

Recruiting

San Miguel,Buenos Aires,1663,Argentina

Novartis Investigative Site

Recruiting

San Miguel de Tucuman,Tucuman,T4000cbc,Argentina

Novartis Investigative Site

Recruiting

Buenos Aires,C1430egf,Argentina

Novartis Investigative Site

Recruiting

Tucuman,4000,Argentina

Australia

Novartis Investigative Site

Recruiting

Maroochydore,Queensland,4558,Australia

Novartis Investigative Site

Recruiting

St Leonards,2065,Australia

Chile

Novartis Investigative Site

Recruiting

Valdivia,Los Rios,5110683,Chile

Novartis Investigative Site

Recruiting

Santiago,RM,7500588,Chile

Novartis Investigative Site

Recruiting

Concepcion,6740,Chile

Novartis Investigative Site

Recruiting

Santiago,7500710,Chile

Colombia

Novartis Investigative Site

Novartis Investigative Site

Recruiting

Bucaramanga,Santander,0001,Colombia

Novartis Investigative Site

Recruiting

Cali,Valle Del Cauca,760046,Colombia

Novartis Investigative Site

Recruiting

Barranquilla,080020,Colombia

Novartis Investigative Site

Recruiting

Bogota,111611,Colombia

Novartis Investigative Site

Recruiting

Cundinamarca,111121,Colombia

Novartis Investigative Site

Recruiting

Medellin,Antioquia,050001,Colombia

Novartis Investigative Site

Recruiting

Barranquilla,Atlantico,080002,Colombia

France

Novartis Investigative Site

Recruiting

Grenoble,38043,France

Novartis Investigative Site

Recruiting

Tours,37044,France

Novartis Investigative Site

Recruiting

Montpellier Cedex 5,34295,France

Novartis Investigative Site

Recruiting

Paris 13,75651,France

Novartis Investigative Site

Recruiting

Paris,75014,France

Novartis Investigative Site

Recruiting

Paris,75018,France

Novartis Investigative Site

Recruiting

Toulouse 4,31054,France

Novartis Investigative Site

Recruiting

Angers Cedex 9,49933,France

Novartis Investigative Site

Recruiting

Toulouse,31400,France

Germany

Novartis Investigative Site

Recruiting

Koeln,50937,Germany

Novartis Investigative Site

Recruiting

Leipzig,04103,Germany

Novartis Investigative Site

Recruiting

Aachen,52074,Germany

Novartis Investigative Site

Recruiting

Mainz,55131,Germany

Novartis Investigative Site

Recruiting

Berlin,13353,Germany

Novartis Investigative Site

Recruiting

Erlangen,91056,Germany

Novartis Investigative Site

Recruiting

Freiburg,79106,Germany

Novartis Investigative Site

Recruiting

Herne,44649,Germany

India

Novartis Investigative Site

Recruiting

Pune,Maharashtra,411001,India

Novartis Investigative Site

Recruiting

Kolhapur,Maharashtra,416001,India

Novartis Investigative Site

Recruiting

New Delhi,110029,India

Novartis Investigative Site

Recruiting

Nashik,Maharashtra,422101,India

Novartis Investigative Site

Recruiting

Puducherry,605006,India

Novartis Investigative Site

Recruiting

New Delhi,110075,India

Novartis Investigative Site

Recruiting

Visakhapatnam,530040,India

Novartis Investigative Site

Recruiting

Ahmedabad,Gujarat,380006,India

Novartis Investigative Site

Recruiting

Kozhikode,Kerala,673008,India

Novartis Investigative Site

Recruiting

Ahmedabad,Gujarat,380015,India

Novartis Investigative Site

Recruiting

Nagpur,Maharashtra,441108,India

Novartis Investigative Site

Recruiting

Secunderabad,Telangana,500003,India

Italy

Novartis Investigative Site

Recruiting

Ancona,AN,60126,Italy

Novartis Investigative Site

Recruiting

Torino,TO,10128,Italy

Novartis Investigative Site

Recruiting

Pisa,PI,56124,Italy

Novartis Investigative Site

Recruiting

Milano,20126,Italy

Novartis Investigative Site

Recruiting

Caserta,CE,81100,Italy

Novartis Investigative Site

Recruiting

Cona,FE,44100,Italy

Novartis Investigative Site

Recruiting

Padova,PD,35128,Italy

Novartis Investigative Site

Recruiting

Roma,RM,00152,Italy

Korea, Republic of

Novartis Investigative Site

Recruiting

Daejeon,Korea,35015,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,Seocho Gu,06591,Korea, Republic of

Novartis Investigative Site

Recruiting

Gwangju Gwangyeoksi,61748,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,04763,Korea, Republic of

Malaysia

Novartis Investigative Site

Recruiting

Seremban,Negeri Sembilan,70300,Malaysia

Novartis Investigative Site

Recruiting

Ipoh,Perak,30450,Malaysia

Novartis Investigative Site

Recruiting

Kuching,Sarawak,93586,Malaysia

Novartis Investigative Site

Recruiting

Petaling Jaya,Selangor Darul Ehsan,46150,Malaysia

Novartis Investigative Site

Recruiting

Kuala Lumpur,59100,Malaysia

Novartis Investigative Site

Recruiting

Selangor Darul Ehsan,68100,Malaysia

Mexico

Novartis Investigative Site

Recruiting

Ciudad de Mexico,Distrito Federal,06700,Mexico

Novartis Investigative Site

Recruiting

Leon,Guanajuato,37160,Mexico

Novartis Investigative Site

Recruiting

Guadalajara,Jalisco,44160,Mexico

Novartis Investigative Site

Recruiting

Morelia,Michoacan,58000,Mexico

Novartis Investigative Site

Recruiting

Merida,Yucatan,97070,Mexico

Novartis Investigative Site

Recruiting

Mexico,07760,Mexico

Romania

Novartis Investigative Site

Recruiting

Bucuresti,011172,Romania

Novartis Investigative Site

Recruiting

Cluj Napoca,400006,Romania

Novartis Investigative Site

Recruiting

Brasov,500283,Romania

Taiwan

Novartis Investigative Site

Recruiting

Kaohsiung,83301,Taiwan

Novartis Investigative Site

Recruiting

Taichung,40447,Taiwan

Novartis Investigative Site

Recruiting

Taipei,10002,Taiwan

Novartis Investigative Site

Recruiting

Taichung,407219,Taiwan

Novartis Investigative Site

Recruiting

Taipei,11217,Taiwan

Novartis Investigative Site

Recruiting

Taoyuan,33305,Taiwan

United Kingdom

Novartis Investigative Site

Recruiting

Birmingham,B15 2th,United Kingdom

Novartis Investigative Site

Recruiting

Leicester,Le1 5ww,United Kingdom

United States

Pinnacle Research Group LLC

Recruiting

Anniston,Alabama,36207-5710,United States

Brittany McNaron

Phone: 256-236-0055

Email: bmcnaron@pinnacletrials.com

Vishala L Chindalore

Homestead Assoc In Research Inc

Recruiting

Homestead,Florida,33033,United States

Yamilko Lugo

Phone: 305-246-0873

Email: ylugo@associatesinresearch.com

Gilberto Seco

Washington Univ School Of Medicine

Recruiting

Saint Louis,Missouri,63110,United States

Phone: 314-362-8681

Reema Syed

UMC New Orleans

Recruiting

New Orleans,Louisiana,70112,United States

Stephen Lindsey

Madeline Young

Email: madeline.young@lcmchealth.org

Integral Rheumatology and Immunology Specialists IRIS

Recruiting

Plantation,Florida,33324,United States

Ana Santana

Phone: [954-476-2338](tel:954-476-2338)

Email: asantana@irisrheumatology.com

Guillermo Valenzuela

University of Calif Irvine Med Cntr

Recruiting

Irvine,California,92660,United States

Bryan Robles

Phone: [714-456-5376](tel:714-456-5376)

Email: bsrobles@hs.uci.edu

Sheetal Desai

University Of Maryland

Recruiting

Baltimore,Maryland,21201,United States

Jessica Brown

Email: jbrown5@som.umaryland.edu

Violeta Rus

Emory University

Recruiting

Atlanta,Georgia,30307,United States

Arezou Khosroshahi

John Varghese

Email: john.varghese@emory.edu

West Tennessee Research Institute

Recruiting

Jackson, Tennessee, 38305, United States

Phone: [731-664-7824](tel:731-664-7824)

Jacob A. Aelion

Illinois Bone And Joint Institute

Recruiting

Hinsdale, Illinois, 60521, United States

Angela R Crowley

Swarnika Sampat

Email: swarnnie@gmail.com

Advanced Medical Research

Recruiting

La Palma, California, 90623, United States

Farrukh Ahmed

Phone: [562-867-8195](tel:562-867-8195)

Email: farrukh@aomed.org

Gerald Ho

Thomas Jefferson University

Recruiting

Philadelphia, Pennsylvania, 19107, United States

Arya Patel

Email: arya.patel@jefferson.edu

Irene Tan

Accurate Clinical Research

Recruiting

Lake Charles, Louisiana, 70601, United States

Enrique Mendez

Jacob Seep

Email: jseep@accurateclinicalresearch.com

Novel Research LLC

Recruiting

Bellaire, Texas, 77401, United States

Hina Arshad

Email: hina@novelresearch.net

Wajeaha Yousaf

Ahmed Arif Medical Research Center

Recruiting

Grand Blanc, Michigan, 48439, United States

Ali Karrar

Aya Elbakheet

Phone: [810-953-8700](tel:810-953-8700)

Email: aya@aamrc.net

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email:

Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: novartis.email@novartis.com

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05624749>
2. [#trial-eligibility](#)
3. <tel:256-236-0055>
4. <mailto:bmcnaron@pinnacletrials.com>
5. <tel:305-246-0873>
6. <mailto:ylugo@associatesinresearch.com>
7. <tel:314-362-8681>
8. <mailto:madeline.young@lcmchealth.org>
9. <tel:954-476-2338>
10. <mailto:asantana@irisrheumatology.com>
11. <tel:714-456-5376>
12. <mailto:bsroble@hs.uci.edu>
13. <mailto:jbrown5@som.umaryland.edu>
14. <mailto:john.varghese@emory.edu>
15. <tel:731-664-7824>
16. <mailto:swarnnie@gmail.com>
17. <tel:562-867-8195>
18. <mailto:farrukh@aomed.org>
19. <mailto:arya.patel@jefferson.edu>
20. <mailto:jseep@accurateclinicalresearch.com>
21. <mailto:hina@novelresearch.net>
22. <tel:810-953-8700>
23. <mailto:aya@aamrc.net>
24. <tel:+41613241111>
25. <mailto:>
26. <tel:1-888-669-6682>
27. <mailto:novartis.email@novartis.com>